Tedopi combinations show survival signals in lung cancer, but Phase 2 trial has not demonstrated superiority to chemotherapy
In a 106-patient trial, both Tedopi combinations had one-year survival rates above 40%. However, statistical testing compared the results against a prespecified benchmark. Whether the combinations outperform chemotherapy remains to be confirmed in larger studies.